Author: Kathir J

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China^[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively^[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia^[3], but is still only 8.2% for anaemia patients in non-dialysis CKD^[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

SHENZHEN, CHINA – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix^®) (the “Product”, marketed as Opzelura^® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.

As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.

The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).

Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.

As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement^[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo^[2].

It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million^[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura^®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)^[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.

The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura^®. Opzelura^® and the Opzelura^® logo are registered trademarks of Incyte.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

1. China Insights Consultancy’s industrial report
2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.
3. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

4. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

 

TimesNewswire / March 13, 2026 – On the afternoon of March 6, 2026, the Guangdong provincial delegation held an open meeting during the Fourth Session of the 14th National People’s Congress in Beijing. The event drew 277 journalists from 111 media outlets, including 61 foreign organizations. Reporters asked questions actively; delegates answering included Huang Kunming, Secretary of the CPC Guangdong Committee, and Meng Fanli, Governor of Guangdong. The meeting was chaired by Huang Chuping, Chairman of the Standing Committee of the Guangdong Provincial People’s Congress.

A Xinhua News Agency reporter noted that during his inspection of Guangdong in November 2025, Chinese President Xi Jinping gave guidance for the province’s scientific planning for the 15th Five-Year Plan period, encouraging Guangdong to take the national lead, set an example for the country, and shoulder greater responsibilities. The reporter asked about Guangdong’s implementation plans. Huang Kunming outlined the province’s vision and key priorities for the year in four areas: “strengthening the two cornerstones of industry and technology,” “advancing reform and opening up while adhering to the mass line,” “expanding into county-level areas and the maritime domain,” and “energizing the two main drivers of enterprises and talent.”

Huang Kunming said Guangdong has vigorously promoted the mutual reinforcement of industry and technology in recent years, leading to the province’s top ranking in regional innovation capability for nine consecutive years. The nine mainland cities in the Guangdong‑Hong Kong‑Macao Greater Bay Area saw foreign trade imports and exports rise 4.4% despite headwinds, and actual use of foreign capital increase 11.3%. “Guangdong‑made products” perform strongly across China and overseas, injecting momentum into the province’s high‑quality development. As Guangdong begins the crucial stage of the 15th Five‑Year Plan period, it aims to cultivate more industrial clusters worth hundreds of billions or trillions of yuan in emerging fields such as 6G, the low‑altitude economy, embodied artificial intelligence, and quantum technology. Huang Kunming extended a warm invitation to media professionals to visit Guangdong, explore its strengths, enjoy its cuisine, and experience the charm of the Lingnan region.

Huang Kunming proactively invited journalists from Macau to ask questions. A reporter from Macau Global Chinese Business News asked what message he had for the Macau press. Huang Kunming said that after years of close collaboration with Macau, both the “hardware and software” foundations have become increasingly mature. Guangdong offers numerous advantages, significant opportunities, and broad space for growth. He welcomed insightful people from all sectors in Macau—especially young people—to come to Hengqin to start or expand businesses or to work.

Responding to a question from a China Media Group reporter, Governor Meng Fanli noted that Guangdong has the largest manufacturing sector in China. During the 15th Five‑Year Plan period, Guangdong will prioritize accelerating high‑quality development of the service sector as a key task in advancing industrial and economic upgrading. The focus will be on “advancing six key dimensions and fostering a robust industrial ecosystem.” The six dimensions are integration, high‑end advancement, digital intelligence, green development, internationalization, and diversification. At the same time, the province will cultivate an industrial ecosystem that supports healthy, rapid growth in services, increase investment in service industries, and build world‑class industrial parks alongside diverse online and offline platforms and carriers.

At the 1.5‑hour interactive session, journalists repeatedly raised questions on hot topics about Guangdong’s development. Delegates responded directly and candidly, sharing their experiences in office and outlining future plans, conveying determination and confidence in advancing during the 15th Five‑Year Plan from multiple perspectives.

Contact: Albert Huang

Tel: 0086-15810014610

E-mail: 1713543383@qq.com

In modern financial markets, mathematics has long served as the invisible framework behind stability, efficiency, and long-term growth. From options pricing to high-frequency trading algorithms, many of the world’s most successful financial systems are built upon carefully structured mathematical models. Feather Exchange is applying this same philosophy to cryptocurrency trading through a system it calls MatrixFlow.

For mathematicians analyzing financial systems, the most intriguing aspect of MatrixFlow is its attempt to bring predictability into a market historically defined by volatility. Rather than leaving price movements entirely to unpredictable swings in speculation, Feather Exchange introduces a structured framework where market progression follows clearly defined mathematical boundaries.

The foundation of the system begins with a guaranteed baseline known as the Minimum Daily Price Rise. Each trading day establishes a structural upward movement expressed mathematically as:

Pₜ = Pₜ₋₁ + 0.02

where Pₜ represents the current trading day’s base price and Pₜ₋₁ represents the previous day’s closing price. This formula creates a minimum progression of 0.02 USDT per day, ensuring that the market maintains a consistent forward trajectory over time.

Once this baseline movement is achieved, additional trading activity can push the price higher within a controlled range. The MatrixFlow system defines a daily expansion boundary using the formula:

Pmax = (Pₜ₋₁ + 0.02) × 1.01

This establishes a daily ceiling where the total market expansion cannot exceed one percent beyond the minimum daily progression. From a mathematical standpoint, this creates a bounded growth corridor that allows healthy price discovery while preventing destabilizing spikes.

Beyond price progression, Feather Exchange introduces another mathematically structured mechanism that analysts find particularly innovative: the Feather Escrow Pool. Within this system, participants are able to acquire FTR tokens at a 50 percent discount relative to the previous day’s highest traded price.

This relationship can be expressed simply as:

Escrow Purchase Price = 0.5 × Hₜ₋₁

where Hₜ₋₁ represents the highest traded market price recorded on the previous trading day.

From a financial engineering perspective, this creates a fascinating market dynamic. Traders are given an opportunity to access discounted tokens tied directly to the historical market price, while the structured release of escrow tokens ensures that supply enters circulation in a controlled and transparent manner.

When combined with the price progression framework, the system forms a feedback structure where trading activity, market price, and token distribution reinforce one another. The long-term price trajectory of the system can be approximated by the progression:

Pₙ ≈ P₀ + (0.02 × n)

where n represents the number of trading days. While the actual market price may fluctuate within its daily corridor, the structural baseline ensures continued forward movement.

For mathematicians studying market design, the significance of MatrixFlow lies in its attempt to transform cryptocurrency trading from a purely speculative environment into one governed by defined economic rules. Markets that operate entirely without structure often experience violent boom-and-bust cycles. By contrast, systems built around predictable mathematical relationships tend to encourage longer-term participation and greater ecosystem stability.

Feather Exchange appears to be applying this philosophy directly into its trading architecture. Instead of relying solely on market sentiment, the platform introduces formulas that guide how price progression, supply release, and discounted participation interact within the ecosystem.

As the exchange prepares for its upcoming 2026 Shareholder Pre-Launch Event, analysts are beginning to examine whether structured systems like MatrixFlow could represent an important step forward in digital asset exchange design.

For mathematicians observing the evolution of financial markets, the concept behind MatrixFlow raises an important possibility: that the next generation of crypto exchanges may not be defined by speculation alone, but by carefully engineered economic structures where mathematics becomes the foundation of sustainable trading.

 

On Saturday, February 28, 2026, our domain was taken offline in a coordinated cyberattack. We cannot name who gave the order. But when you lay out who benefits, who had the means, and why the timing matters, the trail does not scatter. It converges.

The moment a website goes dark is rarely just a technical glitch. It is the final symptom of a story that got too close to the sun. Forensic analysis of the attack on KnowSulu.ph points to a coordinated, multi-vector assault routed through Luxembourg, the Channel Islands, and a data center in Curaçao long associated with shell companies and anonymous servers. This was not opportunistic. It was surgical.

To understand who benefits from a world that no longer knows, look at what we were publishing. Our investigation into what we called the “Horizon Blueprint” traced the financial architecture of the Sulu heirs’ $15 billion claim against Malaysia back to Therium Capital Management, a litigation funder operating through a Jersey shell. We drew a direct line to the UK Post Office Horizon scandal — where Therium funded the case, the public celebrated a victory, and the victims received scraps while nearly £46 million of a £58 million settlement vanished into legal fees and funder returns. Same model. Vastly larger scale.

We also exposed what we called the Manila Conclave — a meeting between the claimants’ legal counsel and individuals with no business being near a courtroom. The director of a London-based intelligence consultancy whose stated work includes influence operations and, in his own words, “manipulating governments through public opinion.” A former CIA station chief. A figure with deep ties to U.S. intelligence operations across Southeast Asia. Three people whose careers were built in the grey zone between corporate security and state-sponsored covert action. You do not hire that room for a legal strategy session.

Now consider the calendar. The attack came weeks before a critical hearing at the Royal Court of Jersey, where counterclaims alleging an “unlawful means conspiracy” have been filed against the Sulu heirs, their lawyers, and Therium itself. The discovery phase was imminent. We exposed the timeline of meetings between lawyers and intelligence operatives, finance trails, modus operandi and motives. All of it pointed toward a Jersey courtroom — and someone, the evidence suggests, could not allow that.

We are not in the business of naming culprits without proof. But place the pieces on the table: a funder with over $20 million at risk and a conspiracy case closing in; an intelligence consultancy with the stated capacity to conduct covert influence operations; a legal team facing potential exposure in a foreign court; and a targeted, professional attack on the one publication connecting those dots — weeks before the deadline that mattered most. Every trail points to the same crossroads. We leave it to you to name the intersection.

What they miscalculated is that the story does not live on a server. It lives in court filings, in financial disclosures, in the memories of the people who were in that room in Manila. The reporting continues. And the scale of what was deployed to silence us — coordinated, multi-jurisdictional, professional — is the loudest confirmation yet that what we published was true. You do not bring that kind of firepower to bear on a story that does not matter.

We are back. Find us, read us, and share the work at know-sulu.ph. The truth belongs to the people of Sulu, and to everyone who believes that those who profit from silence should not be allowed to keep it.

Share the story. Archive it. Pass it forward.

Read full article: https://know-sulu.ph/the-untold-sulu-story/silencing-the-truth-the-takedown-files-who-took-down-knowsulu-ph-and-why

Peter Peralta

Editor, Know-Sulu.ph

peterp@know-sulu.ph

As the world marks International Women’s Day, CGTN published an article highlighting China’s progress in advancing women’s development at home and promoting gender equality globally. It examines how Chinese women are playing an increasingly prominent role in innovation and modernization, and how China’s initiatives and international cooperation are helping women around the world thrive and shine.

Li Ying, a member of the 14th National Committee of the Chinese People’s Political Consultative Conference (CPPCC), Wednesday outlined her vision for China’s maritime future – “bigger, smarter, greener” – at the first group interview of the annual session of China’s top political advisory body.

Li, a professor at Dalian Maritime University, highlighted China’s world-leading maritime fleet, its first domestically-built large cruise ship, and green port advances, including eight zero-carbon pilot ports and 70% of global new green ship orders.

The maritime scientific researcher is a shining example of the growing force of female talent in China’s technology sector, where women now account for nearly half and are increasingly taking on leadership roles in driving innovation across industries.

This momentum in women’s development is highlighted by wider recognition, especially ahead of International Women’s Day on March 8, when Chinese President Xi Jinping extended greetings and best wishes to the country’s women of all ethnic groups and walks of life.

Xi’s greetings echo a long-standing commitment to women’s empowerment. Women play an important role in creating, promoting and carrying forward human civilization, he has said. “On the new journey of Chinese modernization, every woman is a star.”

‘Women hold up half the sky’ in China

In China, the women’s development has always been an integral part of the country’s modernization efforts, with steady progress achieved across education, health and economic participation.

Targeted poverty alleviation since 2013 has helped lift millions of women out of poverty, contributing to a moderately prosperous life for about 690 million women. Meanwhile, the maternal mortality rate fell by 76.9% from 61.9 per 100,000 in 1995 to 14.3 per 100,000 in 2024, far below the global average, according to a white paper.

Women today account for over 45% of the country’s sci-tech workforce and more than half of internet entrepreneurs, milestones that testify to the Chinese saying that “women hold up half the sky.”

These accomplishments are rooted in institutional guarantees and decisive actions. Gender equality is enshrined as a basic national policy, while policies such as targeted poverty reduction, vocational training, universal education access and improved healthcare provide systematic support for women’s development.

“In the new era, Chinese women, more confident and vibrant than ever before, are taking part in the whole process of state and social governance,” Xi has once observed. “They are writing a splendid history of the cause of women in China.”

China builds bridges for global women’s progress

On the international stage, China has engaged in global governance on women’s issues, established platforms for exchange and cooperation between Chinese and foreign women, and contributed to fostering an international environment conducive to women’s development.

By 2025, China had trained more than 200,000 women professionals from over 180 countries and regions, delivered more than 100 training programs for women and children in the Global South and carried out women’s empowerment projects in more than 20 countries, reflecting its commitment to advancing gender equality through concrete South-South cooperation.

China has also co-established the UNESCO Prize for Girls’ and Women’s Education, and launched projects advancing digital education, healthcare and vocational skills for girls in Africa.

A significant milestone came last year, when Beijing hosted the Global Leaders’ Meeting on Women to commemorate the 30th anniversary of the Fourth World Conference on Women, which was also held in the Chinese capital in 1995.

Addressing the meeting back in October, Xi called for efforts to support the UN’s central role, address women’s needs in developing countries, create cooperation platforms and deepen exchanges so as to “help women across the world thrive and shine together.”

The Chinese president also announced new measures, including a $10 million donation to UN Women and $100 million from China’s Global Development and South-South Cooperation Fund for projects benefiting women and girls over the next five years.

The country, he added, will support 1,000 “small and beautiful” livelihood programs that prioritize women and girls as beneficiaries, invite 50,000 women worldwide to China for exchange and training and establish a Global Center for Women’s Capacity Building.

Nahla Haidar, chair of the UN Committee on the Elimination of Discrimination against Women, noted that China’s practices not only advance domestic development but also provide valuable experience for the region and the world.

https://news.cgtn.com/news/2026-03-08/How-China-helps-build-a-world-where-women-thrive-and-shine-1LkU1J9Y6Zi/p.html

Why has there been a surge in root-based upbringing in China Is it due to the influence of Canghai Chuandeng, which is spearheading the contemporary revival of Eastern education

Zhengzhou, China – As family education continues to evolve in China, a new parenting philosophy rooted in cultural heritage and supported by systematic growth companionship is gaining momentum. As an innovator in the family education ecosystem, Mengruibao Family Education Platform is advancing the concept of “Root-System Parenting,” introducing a comprehensive growth companion model that supports children and families throughout every stage of development while building a collaborative and thriving “parenting ecosystem.”

From Philosophy to System: A New Paradigm of “Root-System Parenting”

In an era defined by globalization and digital transformation, families increasingly face the challenge of helping the next generation embrace the world while maintaining a strong cultural identity and inner grounding. Mengruibao’s concept of “Root-System Parenting” responds to this challenge by drawing from the values of Chinese cultural heritage and family ethics, transforming them into modern, accessible educational practices.

Rather than focusing solely on individual educational services, Mengruibao emphasizes the creation of a holistic ecosystem. By integrating cultural values with practical family education solutions, the platform converts abstract ideas about upbringing into tangible experiences that support children’s emotional, intellectual, and cultural development.

Full-Cycle Growth Companionship for Children and Families

At the core of Mengruibao’s initiative is its Full-Cycle Growth Companion Program, designed to support both children and families through every stage of development. This approach recognizes that effective education extends beyond the child to include the entire family environment.

The program focuses on several key dimensions:

Lifecycle coverage: Supporting development from early childcare and foundational education to talent cultivation and personal growth.

Family participation: Empowering parents through family education programs, workshops, and guidance systems so they become active partners in their children’s development.

Holistic development: Encouraging growth in cultural identity, character formation, and personal capabilities.

Through this model, education becomes a continuous part of everyday family life, allowing values such as responsibility, cultural awareness, and personal resilience to develop naturally over time.

Building a “Parenting Galaxy”: A Collaborative Education Ecosystem

Mengruibao believes that sustainable innovation in family education requires more than a single institution—it requires an interconnected ecosystem. The platform is therefore building what it describes as a “Parenting Galaxy,” with families at the center and educators, institutions, and industry partners forming a collaborative network around them.

Within this ecosystem, Mengruibao not only provides growth programs for families but also supports educators and organizations through training, methodology systems, and resource-sharing frameworks. This creates a continuous cycle of method validation, standards development, and ecosystem co-creation, helping advance the overall quality of family education services.

By empowering educators and institutions, Mengruibao aims to ensure that high-quality family education resources can reach more communities and support a broader transformation of the industry.

From the Heartland of China to a Global Vision for Family Education

Originating from China’s Central Plains—one of the cradles of Chinese civilization—Mengruibao draws inspiration from traditional cultural wisdom while translating it into modern educational frameworks suited to today’s families.

Looking ahead, the platform plans to further expand its educational ecosystem by welcoming partners and collaborators from across regions and sectors. Through this collaborative approach, Mengruibao seeks to nurture a new generation of young people who possess both global perspectives and deep cultural roots.

In Mengruibao’s envisioned “parenting galaxy,” every family represents a star, and every educator becomes a bearer of light. As education reconnects with the deeper roots of cultural identity and human growth, a new vision of family education—sustainable, culturally grounded, and globally relevant—is gradually taking shape.

Toronto, Canada –Paradex has announced that the Token Generation Event for its native token, $DIME, is expected to take place soon. The launch represents the next phase in the exchange’s development.

Institutional Background and Market Growth

Paradex was developed by the team behind Paradigm, an institutional crypto derivatives liquidity network that has processed more than $1 trillion in trading volume. That background is reflected in Paradex’s focus on execution quality, capital efficiency, and market structure.

Since launching their on-chain perpetuals exchange, Paradex has recorded:

• Over $250 billion in cumulative trading volume
• Approximately $550 million in open interest
• More than 75,000 users
• Peak daily trading volume above $3 billion

The exchange operates with an offchain central limit order book (CLOB) for matching, and settles transactions through a high-throughput Layer 2 appchain secured by zk-STARK proofs on Ethereum.

Focus on Market Structure and Privacy

A key differentiator for Paradex is its approach to information exposure. On transparent blockchains, position sizes and liquidation levels can often be observed publicly. Paradex encrypts sensitive state data prior to settlement while using zero-knowledge proofs to maintain validity. Access to detailed account information is restricted to verified users.

In addition, the exchange incorporates:

• Zero trading fees for retail participants
• Retail Price Improvement flow segmentation
• A no auto-deleveraging risk model
• Onchain vault infrastructure for yield strategies

These features are designed to reduce execution friction and mitigate structural risks that have historically limited institutional participation in decentralized derivatives markets.

$DIME and Network Alignment

According to Messari’s research coverage, $DIME will launch on Paradex’s spot market and will serve as the native gas token of Paradex Chain.

Messari notes that the token is structured to reduce the traditional conflict of interest between equity holders and tokenholders by directing economic value accrual to the $DIME token itself. Rather than implementing automatic buyback formulas, Paradex intends to conduct buybacks on a discretionary basis, with decisions guided by market conditions and ecosystem considerations.

Token Allocation Overview

Messari outlines the following allocation structure for $DIME:

• 25.1 percent Core Contributors
• 25.0 percent Community Airdrop
• 20.0 percent to Season 2 XP holders
• 5.0 percent to Pre-Season and Season 1 XP holders
• Fully unlocked at launch
• 21.6 percent Ongoing Community Rewards
• 13.4 percent Paradigm Shareholders
• 10.4 percent preferred equity investors subject to a 12-month linear unlock beginning one month after listing
• percent common equity holders
• percent reserved for Paradigm’s balance sheet
• 6.0 percent Foundation Budget
• 5.0 percent Liquidity Programs
• 3.9 percent Future Core Contributors and Advisors

80% of the tokens allocated to Core Contributors and Paradigm shareholders are subject to performance-based unlock conditions. The remaining 20 percent follows a time-based vesting schedule, with 25 percent unlocking one year after listing and the remainder vesting monthly over the following 36 months.

This structure is intended to align long-term incentives between contributors and the broader community.

Looking Ahead

 

Paradex has stated that it plans to expand beyond perpetual futures into spot markets, options, real-world asset products, and more. The $DIME TGE represents a shift toward a network model in which the token underpins economic coordination and value accrual across the platform.

With measurable trading activity, defined tokenomics, and a focus on privacy-preserving infrastructure, the upcoming launch of $DIME will provide a clearer view into how Paradex intends to scale its on-chain derivatives model over the long term.

Further details regarding timing and listing specifics are expected to be released in the coming days. Users can check Paradex’s socials for more information.

About Paradex

Paradex is a privacy-focused decentralized perpetual futures exchange built on its own high-performance Layer 2 appchain using the Starknet stack. The platform combines an off-chain central limit order book for execution with zk-STARK-secured on-chain settlement to deliver centralized-level efficiency within a self-custodial framework.

Developed by the team behind Paradigm, an institutional crypto derivatives liquidity network that has processed over $1 trillion in trading volume, Paradex emphasizes market structure, capital efficiency, and position confidentiality. The exchange currently supports more than 100 markets and integrates features such as Retail Price Improvement flow segmentation, a no auto-deleveraging risk model, and on-chain vault infrastructure.

Paradex aims to expand its ecosystem beyond perpetual futures into spot markets, options, real-world asset products, and more, positioning itself as a broader on-chain financial infrastructure platform.

For more information, users can visit Paradex’s official website and social channels.

Social Links

X: https://x.com/paradex

Discord: https://discord.com/invite/paradex

Telegram: https://t.me/paradex

Media Contact

Brand: Paradex

Contact: Media team

Email: support@paradex.trade

Website: https://paradex.trade

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.

About CMS-D008

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.

Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity

Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat^[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030^[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying^[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics^[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.

CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution

CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.

The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.
2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23
3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z
4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Tashkent, Uzbekistan – 05/03/2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework.

Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter.

Asterium’s project is designed to operate fully within this framework.

What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers:

Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems.

Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support.

Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off.

The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment.

How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion.

“This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.”  

What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack.

About FinHarbor

FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets.

Social Links

LinkedIn: https://www.linkedin.com/company/finharbor/

Blog: https://www.finharbor.com/blog

Media contact

Brand: FinHarbor

Contact: Media team

Email: press@finharbor.com

Website:  https://www.finharbor.com/